The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hyperlipidemia drugs market is expected to exhibit stable growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.
The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug type and end-user
Breakup by Drug Type:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at